Clinical Trials Logo

Lymphoma, Large B-Cell, Diffuse clinical trials

View clinical trials related to Lymphoma, Large B-Cell, Diffuse.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 8

NCT ID: NCT03000738 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas

Start date: December 2016
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether the CD16- monocyte/CD16+ monocyte ratio could help predict the prognosis of DLBCL and PTCL.

NCT ID: NCT02772822 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

Start date: June 2016
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to assess the efficiency of SCT400 plus CHOP versus Rituximab plus CHOP in untreated CD20-positive DLBCL Patients. The secondary objective of the study is to evaluate the safety of SCT400 plus CHOP, as well as the presence of human anti-chimeric antibodies (HACA).

NCT ID: NCT02758925 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

CyBeR Association in Relapsed/Refractory DLBCL

CyBeR-Lymph
Start date: June 2016
Phase: Phase 2
Study type: Interventional

Forty percent of patients with diffuse large B cell lymphoma (DLBCL) have primary refractory or relapsed disease (R/R). For these fit patients, standard treatment in second line therapy is high dose therapy with autologous stem cell transplantation (ASCT). In 48% of DLBCL no ASCT is possible due to progressive disease. For these patients or ineligible to transplantation patients, salvage therapy is often rituximab-gemcitabine-oxaliplatine regimen with an overall response rate (ORR) about 50%. Bendamustine in combination with rituximab, used as a single agent in the setting of R/R DLBCL patients, have shown an ORR of 62.7% and 45.8% with a good safety profile. Bendamustine and cytarabine (BAC) showed high synergy in inducing cell death in mantle cell lymphoma and DLBCL cell lines. In a recent phase II study, the combination of cytarabine with Rituximab and Bendamustine (R-BAC) in patients with mantle cell lymphoma who were previously untreated, refractory or relapsed was evaluated. The efficacy and safety of the R-BAC association will be evaluated in this phase II trial enrolling 78 patients with relapsed or refractory DLBCL.

NCT ID: NCT02544724 Not yet recruiting - Clinical trials for Lymphoma, Large B-Cell, Diffuse (DLBCL)

NM-IL-12 (rHuIL‐12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy

Start date: November 2016
Phase: Phase 2
Study type: Interventional

NM-IL-12 is being evaluated as an immunotherapeutic with concomitant hematopoietic regenerating properties for treatment of relapsed/refractory DLBCL, an aggressive type of B-cell non-Hodgkin's lymphoma (NHL). Determination of the maximum tolerated dose (MTD) for NM-IL-12 is not planned in this study, rather, a pre-defined dose of 150 ng/kg will be explored; this dose is based on two safety and tolerability studies of NM-IL-12 in healthy volunteers.